

Supplementary Figure S3. Subgroup analysis of PFS by PD-L1 TC and IC expression for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of events. BEP, biomarker-evaluable population; CI, confidence interval; D, durvalumab; EP, platinum-etoposide; HR, hazard ratio; IC, immune cell; ITT, intention-to-treat; PD-L1, programmed cell death ligand-1; PFS, progression-free survival; T, tremelimumab; TC, tumor cell.

